Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Emergence conference series February 2019
18 slides from Prescient Therapeutics's conference presentation, Feb 25, 2019
Slide 1: Developing Precision Medicines to Beat Cancer
For personal use only DEVELOPING PRECISION MEDICINES TO BEAT CANCER. Prescient Therapeutics Limited (ASX: PTX) Emergence conference series February 2019
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Prescient's Approach: Address the Mutations Causing Cancer
PRESCIENT’S APPROACH: ADDRESS THE MUTATIONS CAUSING CANCER For personal use only Cells divide Sometimes over and over mistakes are made MUTATIONS CANCER 3 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 4: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE For personal use only • Deep clinical pipeline with 4 data readouts expected in the next 18 months DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 BREAST CANCER PTX-200 (Ph2 pt1 readout Q4 2019) AML PTX-200 (Ph1b readout Q3 2019) OVARIAN PTX-20
Slide 5: Why Is Precision Medicine Changing the Industry?
WHY IS For personal use only PRECISION MEDICINE CHANGING THE INDUSTRY? 5 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 6: Problems with Current "One Size Fits All" Approaches
PROBLEMS WITH CURRENT “ONE SIZE FITS ALL” APPROACHES For personal use only • Without precision medicine, patients are treated the same regardless of the differences between individuals. • A “one size fits all” approach leads to poor outcomes, and exposure to serious risks Untargeted drug Benefit No
Slide 7: People Aren't the Same…Nor Are Tumours
PEOPLE AREN’T THE SAME…NOR ARE TUMOURS For personal use only • Personalized medicine takes into account individual tumour variability » Different tumours have different drivers! • This precise, targeted personalized therapy is a more effective way of treating cancer patients • Huge area of industry
Slide 8: Examples of Precision Medicine Approaches
EXAMPLES OF PRECISION MEDICINE APPROACHES Disease Target Drug Status For personal use only Chronic Myeloid Bcr-Abl Gleevec has increased 5-year survival rate Gleevec for CML from 31% to 90% (1990s-2012) Leukemia (95% of patients) Acute Myeloid FLT3 Gilteritinib NDA filed for R/R FLT3-positive AML Le
Slide 9: Big Valuations and Deal Activity in Precision Medicine
BIG VALUATIONS AND DEAL ACTIVITY IN PRECISION MEDICINE For personal use only US$5B US$8B buyout by Eli Lilly Jan 2019 US$5.1B buyout by GSK Dec 2018 US$3.3B US$18B US$964M 9 GOOGLE FINANCE 20 FEB 2019
Slide 10: PTX-200 Novel AKT Inhibition
PTX-200 For personal use only NOVEL AKT INHIBITION BREAST CANCER ACUTE MYELOID LEUKEMIA OVARIAN CANCER 10 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 11: HER2- Breast Cancer Overview
HER2 - BREAST CANCER OVERVIEW For personal use only 80% OF BREAST CANCERS ARE HER2- BUT THIS IS STILL UNDERSERVED BY NEW DRUGS $10.6B $5.4B 2015 2025 11 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 12: Phase 1b Results Very Encouraging
PHASE 1B RESULTS VERY ENCOURAGING For personal use only Typical expectation with current treatments In PTX’s trial we saw 50% 25% OVERALL RESPONSE RATE IN ALL EVALUABLE PATIENTS OVERALL RESPONSE RATE 100% Visual representation of response by OVERALL RESPONSE RATE IN LOCALLY ADVANCED PATIENTS breast
Slide 13: PTX-100: Pursuing Opportunity in RAS and RHO Mutant Cancers
PTX-100 For personal use only PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS AND RHO MUTANT CANCERS 13 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 14: Basket Trials: Taking Targeted Therapies to the Next Level
BASKET TRIALS: TAKING TARGETED THERAPIES TO THE NEXT LEVEL For personal use only • Group patients according to the mutational profile of their tumours, not on the location of tumours • Use a “basket” trial that bundles identifies patients carrying this mutation, and switch it off with a particular t
Slide 15: PTX-100 The Only Drug Targeting RhoA
PTX-100 THE ONLY DRUG TARGETING RHOA • PTX-100 has a unique position in RhoA mutant For personal use only malignancies » Only clinical stage RhoA inhibitor globally • Phase 1 trial in solid tumours completed – safety profile Unmet clinical need established • Basket PK/PD study expected to begin in Q
Slide 16: Case Study – Loxo Oncology
CASE STUDY – LOXO ONCOLOGY (NASDAQ:LOXO) • Lead drug Larotrectnib: targeted therapy for cancers with TRK fusions For personal use only • An unmet need in small patient population (2,500-3,000 cases/year in US) • Pioneered “one trial to launch” basket study • Only 4 years from initiating Phase 1 2014
Slide 17: Investment Summary
INVESTMENT SUMMARY For personal use only A GREAT LAUNCH PAD FOR TRANSFORMATION • Only exposure to hot precision medicine industry on ASX • Underpinned by PTX-200 » Any one of 3 trials a potential company maker » Encouraging data already unfolding in breast cancer • Moonshot on PTX-100 • Excellent te
Slide 18: Contact
For personal use only CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 18 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Emergence conference series February 2019 on 6ix